Trial Data Confirm Heightened Risks With JAK Inhibitor May help patients and clinicians better weigh benefit against adverse effects Jan 26, 2022
Muddled Picture for Antidepressant as Osteoarthritis Pain Reliever Trial in primary care setting fails to confirm benefit seen in specialty clinics Jan 06, 2022
Another Trial, Another PRP Flop in Osteoarthritis Fails to outperform saline in randomized trial Nov 23, 2021
Another Study Confirms Gout Benefit With SGLT2 Inhibitors Gout risk reduction was significantly better than with DPP-4 inhibitors Nov 19, 2021
Biologic Disappoints for Arthritis Achilles' Inflammation But phase III trial did find some patient-oriented benefits Nov 11, 2021
Vitamin D and Disease Prevention: Worth Another Look? Incidence of autoimmune disease decreased by 25-30% with dietary supplements Nov 08, 2021
Early Biologics Better in Juvenile Idiopathic Arthritis After 2 years, more patients on combo biologic/DMARD regimen had inactive disease Nov 08, 2021
No Love for PRP in Ankle Osteoarthritis Trial Dutch researchers throw cold water on popular therapy Oct 26, 2021
How Should Patients With Autoimmune Diseases Approach COVID Vaccination? Mixed messaging and a lack of tailored research leaves providers and patients in the dark Oct 22, 2021
First Interchangeable Humira Biosimilar Approved Cyltezo nabs coveted "interchangeable" status for RA, inflammatory bowel disease, and more Oct 18, 2021
In RA, Little Risk for Recurrent Cancer With Biologic Treatment Results important because most trials excluded patients with previous cancer, researchers note Sep 23, 2021
Statins Not Linked With Rheumatoid Arthritis, Large Study Finds Risks attenuated after adjustment for lipid levels Sep 22, 2021
Lymphoma in RA: Disease Activity Matters Strongest risk factors were baseline disease activity scores and bone erosions Sep 08, 2021
FDA Slaps Restrictions on JAK Inhibitors Over Serious Safety Risks Use for inflammatory conditions limited to those who fail on TNF blockers Sep 01, 2021
New-Onset IBD and IL-17 Inhibitors: What Is the Risk? Underlying inflammatory disease severity should be taken into account Jul 21, 2021
CV Risk in PsA: Do Drugs Matter? Study weighs in on heart safety of TNF inhibitors versus other biologics Jul 19, 2021
Effective Treatments for Hand Osteoarthritis: The Search Goes On Hydroxychloroquine not effective as disease-modifying drug for erosive hand OA, trial confirmed Jul 08, 2021
Rinvoq Shows Promise in Spine Disease 1-year results in ankylosing spondylitis demonstrate efficacy for JAK inhibitor upadacitinib Jul 02, 2021
Target TNF or IL-12/23 in Psoriatic Arthritis? Both TNF inhibitors and ustekinumab were effective in real-world use Jun 30, 2021
New ACR Rheumatoid Arthritis Guideline: Emphasis on Methotrexate Many RA patients succeed with optimized use of the DMARD before adding another medication Jun 28, 2021
Pain Persists in RA, Even Without Inflammation At 5 years, one-third of patients with rheumatoid arthritis still had "unacceptable" pain Jun 22, 2021
Osteoarthritis: A Link With Parkinson's? Inflammation may contribute to both joint and nerve degeneration Jun 09, 2021
Rituximab a Hazard in RA Patients With COVID Poor outcomes were fourfold higher among rituximab users than for those on TNF inhibitors Jun 03, 2021
Plaque Psoriasis Drug Shows Promise for Psoriatic Arthritis Monoclonal antibody targets the IL-23 p19 subunit May 20, 2021
For Safety, One Biologic a Winner in Psoriasis, Psoriatic Arthritis Lower hospitalization rates compared with other biologics or small molecule therapies May 19, 2021
Stopping IL-17 Drug for Axial Spondyloarthritis? Expect Spinal Flares But low disease activity regained if treatment restarted May 11, 2021
The Death of One Little Girl Helped Millions A case more than 35 years ago has spurred discoveries ever since May 07, 2021 podcast
Results Disappoint for Fecal Transplant in Arthritis But interest persists in targeting the gut-joint axis in psoriatic arthritis May 04, 2021
Pegloticase Safe for Dialysis Patients With Gout Significant drop in monthly ESA dose seen after treatment, too Apr 09, 2021
For Enthesitis in Psoriatic Arthritis, Target IL-23 Targeted agent provides relief for many PsA patients Apr 08, 2021
JAK Inhibitor Promising in Psoriatic Arthritis Oral agent noninferior to adalimumab in joint symptoms Apr 01, 2021
FDA Panel Unhappy With Novel OA Pain Drug Latest setback for troubled osteoarthritis biologic Mar 25, 2021
Don't Stop Taltz in Psoriatic Arthritis Significantly more patients relapsed, and more quickly, after withdrawal Mar 10, 2021
JAK Inhibitor a Hit With RA Patients Superior to adalimumab on many patient-reported outcomes Feb 26, 2021
JAK Inhibitor Misses Endpoint in Safety Study. Now What? Major blow to popular class of oral rheumatology drugs Jan 27, 2021
PET Scans Reveal Vascular Inflammation In giant cell arteritis, imaging confirmed clinical response Jan 07, 2021
Spinal Benefits Seen With Cosentyx in PsA First trial to evaluate response of axial symptoms in psoriatic arthritis to biologic treatment Dec 22, 2020
TYK2 Inhibition Promising in Psoriatic Arthritis Phase II study found significant benefits for two doses of novel agent Nov 10, 2020
COVID Complications Common with Rheumatic Disease Adverse outcomes included acute kidney injury and congestive heart failure Nov 08, 2020